Aptinyx Announces Proposed Public Offering of Common Stock
January 09 2020 - 4:08PM
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that it intends
to offer and sell shares of its common stock in an underwritten
public offering. All of the shares sold in the offering will be
sold by Aptinyx. Aptinyx also expects to grant the underwriters a
30-day option to purchase up to an additional 15% of the number of
shares to be issued and sold in the public offering. The offering
is subject to market and other conditions, and there can be no
assurances as to whether or when the offering may be completed, or
as to the actual size and terms of the offering.
Cowen is acting as the sole book-running manager for the
offering.
Aptinyx intends to use the net proceeds received from the
offering to advance the preclinical and clinical development of its
novel NMDA receptor modulators, including NYX-2925, NYX-783, and
NYX-458, in development for chronic pain, PTSD, and cognitive
impairment, respectively, and for working capital and other general
corporate purposes.
The shares of common stock in the public offering will be issued
by Aptinyx pursuant to a shelf registration statement that was
previously filed with, and declared effective by, the Securities
and Exchange Commission (the “SEC”). The offering will be made only
by means of the written prospectus and prospectus supplement that
form a part of the registration statement. A preliminary prospectus
supplement and the accompanying prospectus relating to the public
offering will be filed by the Company with the SEC. Copies of the
preliminary prospectus supplement and the accompanying prospectus
may be obtained, when available, on the SEC's website at
http://www.sec.gov or by contacting Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com or by telephone at (833)
297-2926.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About AptinyxAptinyx Inc. is a clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of proprietary synthetic small molecules for
the treatment of brain and nervous system disorders.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding the potential public offering.
Risks that contribute to the uncertain nature of the
forward-looking statements include: the success, cost, and timing
of the company’s product candidate development activities and
planned clinical studies; the company’s ability to execute on its
strategy; regulatory developments in the United States and foreign
countries; as well as those risks and uncertainties set forth in
the company’s most recent annual report on Form 10-K and in its
other filings and reports with the United States Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Aptinyx undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Investor Contact:Nick SmithAptinyx
Inc.ir@aptinyx.com847-871-0377
Source: Aptinyx Inc.
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024